Zhu, C. Et Al. 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , vol.93 , 1330-1337.

Zhu, C., Zhou, Z., Roos, I., Merlo, D., Kalincik, T., ÖZAKBAŞ, S., ... Skibina, O.(2022). Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , vol.93, 1330-1337.

Zhu, Chao Et Al. "Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis," JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , vol.93, 1330-1337, 2022

Zhu, Chao Et Al. "Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis." JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , vol.93, pp.1330-1337, 2022

Zhu, C. Et Al. (2022) . "Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis." JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , vol.93, pp.1330-1337.

@article{article, author={Chao Zhu Et Al. }, title={Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis}, journal={JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY}, year=2022, pages={1330-1337} }